CVE-2026-21970: Oracle Life Sciences Central Designer Flaw

CVE-2026-21970 Overview

CVE-2026-21970 is a vulnerability in the Oracle Life Sciences Central Designer product of Oracle Health Sciences Applications, specifically affecting the Platform component. This easily exploitable flaw allows a low-privileged attacker with network access via HTTP to compromise the application and gain unauthorized access to critical data, potentially accessing all Oracle Life Sciences Central Designer accessible data.

Critical Impact

Successful exploitation enables attackers with minimal privileges to access sensitive life sciences research data, clinical trial information, and other confidential healthcare data stored within Oracle Life Sciences Central Designer.

Affected Products

• Oracle Life Sciences Central Designer version 7.0.1.0
• Oracle Health Sciences Applications (Platform component)

Discovery Timeline

• January 20, 2026 - CVE-2026-21970 published to NVD
• January 20, 2026 - Last updated in NVD database

Technical Details for CVE-2026-21970

Vulnerability Analysis

This vulnerability represents an authorization bypass or broken access control issue within the Platform component of Oracle Life Sciences Central Designer. The flaw allows authenticated users with low privileges to access data beyond their authorized scope, potentially compromising the confidentiality of critical healthcare and life sciences information.

The vulnerability requires only network access via HTTP and low-level privileges to exploit, making it accessible to any authenticated user on the network. The attack does not require user interaction, and the scope remains unchanged, meaning the vulnerable component is the same as the impacted component.

Root Cause

The root cause stems from improper access control mechanisms within the Platform component of Oracle Life Sciences Central Designer. The application fails to properly validate user privileges before granting access to sensitive data, allowing low-privileged users to access information that should be restricted to higher-privileged accounts or administrators.

Attack Vector

The attack vector is network-based, requiring only HTTP access to the Oracle Life Sciences Central Designer application. An attacker who has obtained low-level credentials (either through legitimate means or credential theft) can leverage this vulnerability to:

1. Authenticate to the Oracle Life Sciences Central Designer application with a low-privileged account
2. Craft HTTP requests that bypass normal access control checks
3. Access critical data that should be restricted to higher-privileged users
4. Exfiltrate sensitive life sciences research data, clinical trial information, or other confidential healthcare data

The vulnerability has high confidentiality impact but does not affect integrity or availability, indicating that while attackers can read unauthorized data, they cannot modify it or disrupt service availability through this specific flaw.

Detection Methods for CVE-2026-21970

Indicators of Compromise

• Unusual data access patterns from low-privileged user accounts accessing sensitive datasets
• HTTP requests to the Platform component that deviate from normal user behavior patterns
• Access logs showing low-privileged accounts retrieving data from restricted areas
• Unexpected spikes in data access volume from individual user accounts

Detection Strategies

• Monitor Oracle Life Sciences Central Designer access logs for unauthorized data access attempts
• Implement User and Entity Behavior Analytics (UEBA) to detect anomalous access patterns
• Configure alerts for low-privileged accounts accessing high-sensitivity data classifications
• Review HTTP traffic to the Platform component for suspicious request patterns

Monitoring Recommendations

• Enable detailed audit logging within Oracle Life Sciences Central Designer
• Implement network monitoring to track HTTP traffic to the application
• Deploy Security Information and Event Management (SIEM) rules to correlate access events
• Conduct regular access reviews to identify potentially compromised accounts

How to Mitigate CVE-2026-21970

Immediate Actions Required

• Apply the Oracle Critical Patch Update from January 2026 immediately
• Review access logs for any signs of prior exploitation
• Implement network segmentation to restrict access to Oracle Life Sciences Central Designer
• Enforce the principle of least privilege for all user accounts

Patch Information

Oracle has addressed this vulnerability in the January 2026 Critical Patch Update. Administrators should apply the patch to all affected Oracle Life Sciences Central Designer version 7.0.1.0 installations. The official security advisory is available through Oracle Security Alert January 2026.

Workarounds

• Implement network-level access controls to restrict HTTP access to the Platform component
• Enable additional authentication mechanisms such as multi-factor authentication (MFA)
• Apply strict firewall rules to limit access to trusted network segments only
• Consider temporarily disabling access for non-essential low-privileged accounts until patching is complete

# Example: Network access restriction configuration
# Restrict access to Oracle Life Sciences Central Designer to trusted networks only
# Add to firewall or network access control list

# Allow access only from trusted management networks
iptables -A INPUT -p tcp --dport 80 -s 10.0.0.0/8 -j ACCEPT
iptables -A INPUT -p tcp --dport 443 -s 10.0.0.0/8 -j ACCEPT
iptables -A INPUT -p tcp --dport 80 -j DROP
iptables -A INPUT -p tcp --dport 443 -j DROP